Drugs / Nab-PTX
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04781413 | Mar 2021 → Mar 2024 | gastric carcinoma | Ruijin Hospital | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05528367 | Jan 2022 → Jun 2024 | gastric cancer | Zhejiang Cancer Hospital | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 0 | NCT07033689 Background | Jan → Dec 2026 expected | pancreatic ductal adenocarcinoma | SONIRE Therapeutics Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nab-PTX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05528367 ↗ |
| Known as | Nanoparticle albumin-bound paclitaxel | “Nanoparticle albumin-bound paclitaxel (Nab-PTX) is safer and more effective than PTX in the peritoneal metastasis.” PMID 34877867 ↗ Dec 2021 |